Abstract
We present a case of a patient treated with etanercept (TNF-a antagonist) for psoriatic arthritis, who then developed clinical symptoms of lepromatous leprosy. She presented with multiple erythematous plaques on trunk, face and extremities, saddle nose deformity, alopecia, articular deformities of the feet and peroneal neuropathy. The clinical suspicion of Hansen’s Disase was confirmed by the biopsy findings (lepromatous leprosy). On further questioning, the patient stated that her father was diagnosed with leprosy 70 years ago and had spent some years in a leper colony in Spinalonga island in Southern Greece in the 1940s. This first report of Hansen’s disease after administration of etanercept highlights the need of careful risk assessment of patients for whom antiTNF treatment is planned.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO (2004) Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 38:1261–1265
Lopes RV, Ohashi CB, Cavaleiro LH, Cruz RBP, da Veiga RR, Miranda MFR, Yoshikawa TG (2009) Development of leprosy in a patient with ankylosing spondylitis during the infliximab treatment: reactivation or latent infection? Clin Rheumatol 28:615–617
Scollard DM, Joyce MP, Gillis TP (2006) Development of leprosy and type 1 leprosy reactions after treatment with infliximab: a report of 2 cases. Clin Infect Dis 43(2):e19–e22
Camacho ID, Valencia I, Rivas MP, Burdick AE (2009) Type 1 leprosy reaction manifesting after discontinuation of adalimumab therapy. Arch Dermatol 145(3):349–351
Oberstein EM, Kromo O, Tozman EC (2008) Type I reaction of Hansen’s disease with exposure to adalimumab: a case report. Arthritis Rheum 59(7):1040–1043
Freitas DS, Machado N, Andrigueti FV, Reis Neto ET, Pinheiro MM (2010) Lepromatous leprosy associated with the use of anti-TNF α therapy: case report. Rev Bras Reumatol 50(3):333–339
Ridley DS (1974) Histological classification and the immunological spectrum of leprosy. Bull WHO 51:451–465
Hernandez MO, Neves I, Sales JS, Carvalho DS, Sarno EN, Sampaio EP (2003) Induction of apoptosis in monocytes by Mycobacterium leprae in vitro: a possible role for tumour necrosis factor-alpha. Immunology 109(1):156–164
Ehlers S (2005) Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept? Clin Infect Dis 41(Suppl 3):S199–S203
Kim JY, Park JN, Lee JG, Lee YA, Kim YH, Hong SJ, Yang HI, Lee SH (2009) The use of etanercept in a patient with disseminated tuberculosis. Rheumatol Int 29(11):1377–1380
Ramien ML, Wong A, Keystone JS (2011) Severe refractory erythema nodosum leprosum successfully treated with the tumor necrosis factor inhibitor etanercept. Clin Infect Dis 52(5):e133–e155
Chauhan S, Wakhlu A, Agarwal V (2010) Arthritis in leprosy. Rheumatology 49:2237–2242
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lydakis, C., Ioannidou, D., Koumpa, I. et al. Development of lepromatous leprosy following etanercept treatment for arthritis. Clin Rheumatol 31, 395–398 (2012). https://doi.org/10.1007/s10067-011-1903-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-011-1903-2